We are revolutionizing the translational potential of animal models in preclinical research. Discover the latest articles and news about our recent activities.
13 September 2023
PhoenixBio is delighted to be attending the International HBV Meeting in person at the Kobe International Conference Center in Kobe, Japan on September 19th - 23rd, 2023. We'll be sponsoring the conference and providing talks on preclinical models. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.
13 September 2023
PhoenixBio is delighted to be attending the 57th Congress of the European Toxicologists and European Societies of Toxicology in person at the Ljubljana Exhibition and Convention Centre in Ljubljana, Slovenia on September 10th - 13th, 2023. We'll be exhibiting our products & services at booth #35. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you with drug metabolism, pharmacokinetic, and toxicology research.
21 August 2023
It is estimated that 40% of drug candidates have failed to make it to market because of toxicity.¹ One of the most common adverse drug reactions is drug-induced liver injury (DILI), whereby patients experience acute illness, often with symptoms similar to hepatitis and cholestasis. Today, DILI is the leading cause of drug candidate failure and post-market withdrawals.² The high incidence of DILI in clinical trials, and even post-market events, is partly due to the use of conventional animal models at preclinical stages. Conventional models are notoriously poor predictors of efficacy and toxicity in the liver, due to species-to-species variation. In contrast, the PXB-mouse® model, with its humanized liver, provides a highly predictive model of human physiology and human-specific hepatotoxicity, allowing for more accurate prediction of human outcomes, and, therefore, aiding the smooth progression of new therapeutics into the clinic.
7 August 2023
Hepatitis B is a serious and globally prevalent disease with 296 million people worldwide living with chronic hepatitis B virus (HBV) infections. Recent advances in HBV therapeutics have made infection a treatable disease, but they only disrupt certain areas of the HBV lifecycle. As a result, if the therapeutics are withdrawn, patients can relapse. What’s more, long-term use can cause antiviral resistance. To cure the disease, therapeutics need to address every stage of the HBV lifecycle, providing both seroclearance of the hepatitis B surface antigen (HBsAg) and silencing of the genomically integrated HBV DNA. However, investment in this space carries considerable risk as developers struggle to move treatments from animal models to human studies. Notably, human responses to HBV therapies are notoriously difficult to predict and traditional animal models translate poorly to the human environment, causing significant delays, as well as safety, cost, and efficacy concerns.
24 July 2023
How can humanized liver models provide accurate efficacy measurements at each stage of the viral lifecycle? Hepatitis B is a serious global health threat. Around 1.5 million hepatitis B virus (HBV) infections were identified in 2019 alone and around 296 million people are thought to be living with the chronic disease.¹ Researchers are now targeting previously unexplored areas of the viral lifecycle to get closer to developing a complete cure.
10 July 2023
In recent years, we have seen an explosion in the number of adeno-associated virus (AAV) vector-based gene therapies progressing to clinical trial stages, and subsequently an increasing number of regulatory successes. The reasons for this are clear. The versatility of AAV-based platforms makes them prime technology for targeting a range of tissues and pathologies, through their ability to silence, replace or modify genes.
27 June 2023
Generating high-quality, pre-clinical data is always challenging, but it is especially so when developing therapeutics for hepatitis B and D. Since Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) only infect human hepatocytes, conventional animal models instantly pose a challenge as the entire viral lifecycle cannot be observed, and the data often doesn’t translate well to the human environment. These issues can lead to misleading metabolism, pharmacokinetics, efficacy and hepatotoxicity data, which can result in wasted time, money and resources and, potentially, failure at clinical trial stages.
12 June 2023
PhoenixBio is delighted to be attending the EASL Congress in person at the Messe Wien Exhibition Congress Center in Vienna, Austria on June 21st - 24th, 2023. We'll be exhibiting our products & services at booth #E14. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.
